9:34 AM ET 2/26/15 | Morningstar
RELATED QUOTES
10:53 AM ET 2/26/15
Symbol Last % Chg
GRFS.ZY
34.12 0.71%
GRFS
34.14 0.78%
Real time quote.
Grifols reported strong results for 2014, with 22% top-line growth (24% at constant currencies) and a 32% adjusted EBITDA margin. This was slightly below our forecast on the top line, but profitability was stronger than we expected, putting bottom-line performance closer to our forecast. We're maintaining our EUR 34 per share ($39 per ADR) fair value estimate, and we remain confident in Grifols' narrow moat, which rests in its significant cost advantages in the global plasma market. While performance was boosted by the Novartis diagnostics acquisition in January, about 60% of Grifols' revenue is derived from North America, likely giving the firm a strong currency tailwind in 2015 and driving continued double-digit growth this year.
Grifols' plasma sales were weaker in 2014, which we believe is due to ex U.S. Factor VIII pressure and a more competitive U.S. hospital sales environment. The Bioscience division (now 75% of revenue) grew 2.6% in 2014 (4% at constant currencies). Performance has improved each quarter this year, but the 4.8% constant currency growth in the fourth quarter was well below the 8% growth in 2013. We think this is largely due to double-digit declines in sales of the firm's Factor VIII products in a very competitive environment, as recombinant products are increasingly used in emerging markets. However, Grifols noted that the U.S. plasma market was quite competitive in 2014 and that it did increase marketing and negotiate contracts (probably implying some pricing pressure, even in this higher-priced market). We think these comments apply to the immunoglobulin market, confirming recent comments from CSL, which pointed to pricing pressure for its fighting brand Carimune in price-sensitive hospital channels. However, we continue to view the top three global plasma firms as holding significant cost advantages over smaller players, and we think pricing power remains strong for premium brands, which are increasingly used chronically and at home.
Recent GRFS News
- Grifols 2023 Annual Report on Form 20-F filed with the SEC • PR Newswire (US) • 04/19/2024 08:42:00 PM
- Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C. • GlobeNewswire Inc. • 04/18/2024 01:30:00 PM
- Samsung Surpasses Apple in Q1 Smartphone Market; Salesforce in Talks to Acquire Informatica, and More News • IH Market News • 04/15/2024 11:06:48 AM
- Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening • GlobeNewswire Inc. • 04/04/2024 08:00:00 AM
- FedEx Soars 13% with Profits Above Forecasts, Nike Hit by China Slowdown, and Latest News • IH Market News • 03/22/2024 01:07:53 PM
- CNOOC Oil Field Discovery in South China Sea, Grifols Surges 18% After KPMG Approval, and Latest News • IH Market News • 03/08/2024 11:19:59 AM
- Grifols announces positive topline phase 3 fibrinogen clinical trial results • GlobeNewswire Inc. • 02/14/2024 08:16:43 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/26/2024 10:14:35 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/16/2024 11:05:11 AM
- Wall Street Highlights: DocuSign Acquisition Battle, Tesla Berlin Production Halt, and More • IH Market News • 01/12/2024 11:10:50 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/10/2024 06:08:20 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/10/2024 01:59:48 PM
- Wall Street Highlights: Tesla Launches Restyled Model 3, VinFast Unveils Pickup Prototype, and More • IH Market News • 01/10/2024 11:21:31 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/09/2024 07:49:54 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/09/2024 01:25:35 PM
- Grifols Shares Rise on $1.76 Billion Sale of 20% Stake in Shanghai RAAS to Pay Down Debt • Dow Jones News • 12/29/2023 02:59:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/29/2023 02:46:56 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/29/2023 02:40:45 PM
- Grifols launches new solution to facilitate pre-transfusion compatibility testing in multiple myeloma patients • PR Newswire (US) • 11/16/2023 10:00:00 AM
- Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency • GlobeNewswire Inc. • 11/15/2023 01:00:00 PM
- GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023 • GlobeNewswire Inc. • 11/06/2023 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/02/2023 05:25:35 PM
- Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD • GlobeNewswire Inc. • 10/24/2023 10:30:56 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/20/2023 12:36:30 PM
- GigaGen Granted Expansion of Contract with US Department of Defense to Develop Synthetic Human Antibody Treatments for Botulinum Neurotoxins • GlobeNewswire Inc. • 10/19/2023 12:00:00 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM